Quince Therapeutics (NASDAQ:QNCX) Coverage Initiated at Brookline Capital Management

Equities research analysts at Brookline Capital Management began coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. Brookline Capital Management’s price target suggests a potential upside of 411.36% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on the stock. RODMAN&RENSHAW raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. Rodman & Renshaw began coverage on shares of Quince Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $11.00 target price for the company. EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, Maxim Group initiated coverage on Quince Therapeutics in a research note on Thursday, November 7th. They set a “buy” rating and a $6.00 price objective for the company. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Quince Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $8.67.

Quince Therapeutics Stock Performance

Shares of QNCX stock opened at $1.76 on Wednesday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45. The business’s 50 day moving average is $1.59 and its two-hundred day moving average is $1.02. The company has a market capitalization of $77.44 million, a P/E ratio of -1.42 and a beta of 0.74.

Institutional Trading of Quince Therapeutics

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the period. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 as of its most recent SEC filing. Institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.